Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Remifentanil Opioid Anasthetic Action Pathway
Homo sapiens
Drug Action Pathway
Remifentanil is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which acts in the brain, spinal cord, and peripherally. This means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
Remifentanil binds to mu opioid receptors, stimulating the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as GABA is inhibited. Opioids close N-type voltage-operated calcium channels and open calcium-dependent inwardly rectifying potassium channels. This results in hyperpolarization and reduced neuronal excitability. This leads to less activity in the brain which causes an anesthetic effect.
References
Remifentanil Opioid Anasthetic Pathway References
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Nassirpour R, Bahima L, Lalive AL, Luscher C, Lujan R, Slesinger PA: Morphine- and CaMKII-dependent enhancement of GIRK channel signaling in hippocampal neurons. J Neurosci. 2010 Oct 6;30(40):13419-30. doi: 10.1523/JNEUROSCI.2966-10.2010.
Pubmed: 20926668
Chan P, Lufty K. Molecular Changes in Opioid Addiction: The Role of Adenylyl Cyclase and cAMP/PKA System. Progress in Molecular Biology and Translational Science, Volume 137: 203-219, 2016.
Scott LJ, Perry CM: Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-823. doi: 10.2165/00003495-200565130-00007.
Pubmed: 16114980
Scott LJ, Perry CM: Spotlight on remifentanil for general anaesthesia. CNS Drugs. 2005;19(12):1069-74. doi: 10.2165/00023210-200519120-00010.
Pubmed: 16332149
Warner DS, Hindman BJ, Todd MM, Sawin PD, Kirchner J, Roland CL, Jamerson BD: Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Anesth Analg. 1996 Aug;83(2):348-53. doi: 10.1097/00000539-199608000-00025.
Pubmed: 8694317
Patel SS, Spencer CM: Remifentanil. Drugs. 1996 Sep;52(3):417-27; discussion 428. doi: 10.2165/00003495-199652030-00009.
Pubmed: 8875131
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings